Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

LPS and Platelet Activation in Myocardial Infarction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03675789
Recruitment Status : Completed
First Posted : September 18, 2018
Last Update Posted : November 21, 2018
Sponsor:
Collaborator:
Neuromed IRCCS
Information provided by (Responsible Party):
Francesco Violi, University of Roma La Sapienza

Tracking Information
First Submitted Date September 15, 2018
First Posted Date September 18, 2018
Last Update Posted Date November 21, 2018
Actual Study Start Date January 2, 2013
Actual Primary Completion Date July 6, 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: October 8, 2018)
LPS in blood of STEMI, SA patients and controls. [ Time Frame: 1 year ]
LPS will be measured in serum and expressed as concentration (pg/ml)
Original Primary Outcome Measures
 (submitted: September 17, 2018)
LPS, markers of platelet activation, inflammation and marker of gut permeability in blood of STEMI, SA patients and controls. [ Time Frame: At the end of patients' recruitment. ]
Serum LPS, plasma sPselectin, plasma sCD40L, serum CRP and zonulin.
Change History
Current Secondary Outcome Measures
 (submitted: October 8, 2018)
  • LPS in thrombus and intra-coronary blood of STEMI and SA patients. [ Time Frame: 1 year ]
    LPS will be measured in coronary thrombi of STEMI patients and in intra-coronary blood of SA patients and expressed as concentration (pg/ml)
  • sP-selectin in thrombus and intra-coronary blood of STEMI and SA patients. [ Time Frame: 1 year ]
    sP-selectin (a marker of platelet activation) will be measured in coronary thrombi of STEMI patients and in intra-coronary blood of SA patients and expressed as concentration (ng/ml).
  • sCD40L in thrombus and intra-coronary blood of STEMI and SA patients. [ Time Frame: 1 year ]
    sCD40L (a marker of platelet activation) will be measured in coronary thrombi of STEMI patients and in intra-coronary blood of SA patients and expressed as concentration (ng/ml).
  • Escherichia coli-DNA [ Time Frame: 1 year ]
    Escherichia coli-DNA will be searched in serum patients and controls by polymerase chain reaction (PCR).The investigators will evaluate the rate of positivity in the serum of the study population.
  • Histologic and immunohistochemical analyses of thrombus fragments aspirated from a subset of STEMI patients. [ Time Frame: 1 year ]
    Immunoistochemistry on sections obtained from formalin-fixed and paraffin embedded thrombus fragments.The investigators will analyze the composition of thrombus fragments and the presence of LPS , TLR4 and Cathepsin G.
  • HS-CRP in blood of STEMI, SA patients and controls [ Time Frame: 1 year ]
    High sensitivity-C reactive protein will be measuer in serum and expressed as concentration (mg/L).
  • sP-selectin in blood of STEMI, SA patients and controls. [ Time Frame: 1 year ]
    sP-selectin (a marker of platelet activation) will be measured in plasma and expressed as concentration (ng/ml)
  • Soluble CD40L (sCD40L) in blood of STEMI, SA patients and controls. [ Time Frame: 1 year ]
    sCD40L (a marker of platelet activation) will be measured in plasma and expressed as concentration (ng/ml)
  • Zonulin in blood of STEMI, SA patients and controls [ Time Frame: 1 year ]
    Zonulin (a marker of gut permeability) will be measued in serum and expressed as concentration (ng/ml)
Original Secondary Outcome Measures
 (submitted: September 17, 2018)
  • LPS and markers of platelet activation in thrombus and intra-coronary blood of STEMI and SA patients. [ Time Frame: At the end of patients' recruitment. ]
    LPS, sP-selectin, sCD40L in coronary thrombi of STEMI patients and in intra-coronary blood of SA patients.
  • Escherichia coli-DNA [ Time Frame: At the end of patients' recruitment. ]
    Escherichia coli-DNA will be searched in serum patients and controls by polymerase chain reaction (PCR).
  • Histologic and immunohistochemical analyses of thrombus fragments aspirated from a subset of STEMI patients. [ Time Frame: At the end of patients' recruitment. ]
    Immunoistochemistry on sections obtained from formalin-fixed and paraffin embedded thrombus fragments.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title LPS and Platelet Activation in Myocardial Infarction
Official Title Endotoxemia in Coronary Thrombus of Patients With Acute Coronary Syndrome
Brief Summary

Platelets play a key role in the athero-thrombotic process. However, the in vivo mechanism accounting for thrombus growth at site of coronary atherosclerotic lesion has not been fully elucidated. While platelet adhesion and aggregation on the thrombogenic core of atherosclerotic plaque is an established mechanism for thrombus growth, the role of systemic factors, which may contribute to thrombus via amplification and propagation of platelet aggregation, is still to be clarified.

There is a growing body of evidence that lipopolysaccharides (LPS), are implicated in athero-thrombosis. Circulating levels of endotoxins have been associated with human atherosclerosis progression, particularly in smokers or in patients with infections. Furthermore, endotoxins seem to be implicated in the thrombotic process through several mechanisms including up-regulation of macrophage tissue factor expression and amplification of platelet response upon interaction with Toll-like receptor 4. The relationship between endotoxins and platelets may be relevant in the context of acute coronary syndromes as endotoxins could locally amplify platelet-derived thrombus growth but this issue is still unexplored.

Previous studies demonstrated that low-grade endotoxemia is detectable in human circulation, likely as consequence of enhanced gut permeability, and may be responsible for leucocyte-platelet aggregate and eventually thrombosis. The investigators hypothesize that low-grade endotoxemia may be observed in patients with coronary heart disease and may favor, at site of coronary unstable plaque, thrombus growth. To explore this issue, Escherichia Coli (EC)-LPS concentration and biomarkers of platelet activation will be measured in coronary thrombus and intra-coronary blood of patients with STEMI and stable angina (SA), respectively, and in peripheral circulation of both patients and controls. EC DNA will be searched in serum of all patients by polymerase chain reaction (PCR). Furthermore, to substantiate that LPS could be biologically active, immune-histochemical analysis of thrombi and in vitro studies will be performed to assess the interplay between LPS and platelet activation.

Detailed Description

In this case-control study, three groups of patients will be compared: consecutive STEMI patients undergoing to manual thrombo-aspiration during primary percutaneous coronary intervention, patients with chronic stable angina (SA) undergoing elective diagnostic and/or interventional coronary procedure and outpatients without coronary heart disease referring to the ambulatory of the Department of Internal Medicine, I Clinica Medica, Sapienza -University of Rome.

Patients will be recruited from three Centers: i) Department of the Heart and Great Vessels "Attilio Reale", Sapienza -University of Rome; ii) Department of Internal Medicine, I Clinica Medica, Sapienza -University of Rome; iii) Department of Interventional Cardiology, Santa Maria University Hospital, Terni.

The study complied with the Declaration of Helsinki and was approved by the local ethic committees of centers involved.

In patients presenting STEMI, coronary thrombi, when present, or plaque fragments will be aspirated from the culprit coronary artery before stent implantation and collected in EDTA tubes.

Thrombi will be homogenized in 5 mL of a homogenization buffer. Aliquots of thrombi homogenate will be centrifuged. In a subset of STEMI patients, part of the thrombotic material aspirated will be fixed in 4% buffered formaldehyde for histologic and immunohistochemical analyses.

In patients with SA, intracoronary blood will be aspirated from the stented coronary artery, before stenting, and immediately collected in EDTA tubes and centrifuged. Next, supernatant will be removed and stored at -80°C until use.

Peripheral blood samples will be obtained from a radial or femoral artery, before the start of procedure and after stent deployment in STEMI patients, or before balloon dilation and stenting in SA patients and then collected into tubes with or without 3.8% sodium citrate and EDTA tubes and centrifuged to obtain supernatant. Blood samples of controls group will be obtained from patients after supine rest for at least 10 min and taken into tubes with or without 3.8% sodium citrate and in EDTA tubes and centrifuged to obtain supernatant. Plasma and serum aliquots will be stored at -80°C in appropriate cuvettes until assayed.

Complete haemochrome, blood glucose, lipid profile, fibrinogen, creatinine, creatine kinase-MB and troponin T will be evaluated using standard methods.

sCD40L and sP-selectin levels will be measured with a commercial immunoassay in aliquots of plasma, thrombus homogenate and intracoronary blood.

Lipopolysaccharide (LPS) levels in serum and thrombus will be measured using a commercial ELISA kit.

A PCR reaction for specific amplification of a region of the 16S ribosomal RNA gene of Escherichia coli will be developed.

Serum zonulin levels will be measured using a commercial ELISA kit.

Immunoistochemistry (IHC) will be performed on sections obtained from formalin-fixed and paraffin embedded thrombus fragments aspirated from a subset of STEMI patients. After rehydration and antigen retrieval slides will be incubated with primary antibodies respectively to LPS, TLR4 and Cathepsin G, then washed in phosphate saline buffer and incubated with a secondary universal antibody. Immunoreactions will be detected with diaminobenzidine.

.

Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples Without DNA
Description:
Peripheral blood, aspirated intra-coronary blood, aspirated coronary thrombi, aspirated plaque fragments from coronary culprit lesions.
Sampling Method Non-Probability Sample
Study Population
  1. STEMI patients referred to the catheterization laboratory for PPCI, who will undergo to manual coronary thrombo-aspiration, that fulfilled the inclusion/exclusion criteria, with a sufficient thrombotic material (≥1 mm3).
  2. patients with chronic stable angina (SA) undergoing elective diagnostic and/or interventional coronary procedure, undergoing to intracoronary blood aspiration
  3. outpatients without coronary heart disease matched for age, gender and comorbidities like diabetes and hypertension
Condition
  • Myocardial Infarction
  • Acute Coronary Syndrome
Intervention Not Provided
Study Groups/Cohorts
  • STEMI
    50 STEMI patients treated with standard therapy undergoing to primary percutaneous coronary internention (PPCI). Thromboaspiration will be performed whenever possible (when the anatomy of the coronary artery - curve and size- allowed it) in all patients with a TIMI Flow 0 and in all patients with a visible thrombus if TIMI Flow was 1 or more.
  • Stable angina
    50 stable angina (SA) patients on standard therapy, undergoing to intracoronary blood aspiration during elective diagnostic and/or interventional coronary procedure, matched for age, sex and comorbidities with the 50 STEMI patients.
  • Controls
    50 outpatients without coronary heart disease, matched for age gender and comorbidities like diabetes and hypertension with the 50 STEMI patients. Peripheral blood samples will be collected during routine patient monitoring.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: September 17, 2018)
150
Original Actual Enrollment Same as current
Actual Study Completion Date November 5, 2018
Actual Primary Completion Date July 6, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

For STEMI patients:

  • diagnosis of STEMI based on the current European Guidelines

For SA patients:

  • diagnosis of SA defined according to the European Guidelines as lack of episodes of coronary instability for at least 6 months prior to admission

For control subjects:

  • outpatients without diagnosis of coronary heart disease

Exclusion Criteria:

  • estimated glomerular filtration rate less than 30 ml/min/m2
  • acute or recent systemic infections (3 weeks)
  • treatment with systemic corticosteroids
  • treatment with oral anticoagulants
  • malignancy
  • lack of consent to participate

Additional exclusion criteria for STEMI patients were symptoms duration>12 h, rescue PCI, in-stent thrombosis and anatomical difficulty in reaching the lesion.

Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 95 Years   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Italy
Removed Location Countries  
 
Administrative Information
NCT Number NCT03675789
Other Study ID Numbers EMI-Sapienza
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement
Plan to Share IPD: Undecided
Responsible Party Francesco Violi, University of Roma La Sapienza
Study Sponsor University of Roma La Sapienza
Collaborators Neuromed IRCCS
Investigators
Study Chair: Francesco Violi, MD Sapienza University of Rome
PRS Account University of Roma La Sapienza
Verification Date November 2018